Research summaries
Focused summaries set out the question a study asks, the kind of evidence it offers, and the limits that should remain visible when research on ibogaine, GDNF, and Parkinson’s is discussed.
Independent information services
Services
Guides, comparisons, and research summaries from Slow Ledger 10 on Ibogaine, Gdnf And Parkinson's: A Research Digest.
Information for careful orientation—not medical advice or treatment guidance.
A quieter way to assess claims
Context before conclusions.
These offerings are informational: they organize difficult material into plain language, distinguish preliminary findings from established care, and keep safety and uncertainty visible. The main research overview provides the wider context for the questions gathered here.
Parkinson’s disease is a progressive neurological disorder, but the range of symptoms and research questions is broad; the National Institute of Neurological Disorders and Stroke overview of Parkinson’s disease is a useful baseline for understanding why careful interpretation matters.
What this resource provides
Practical reading tools for an uncertain field.
Each service is designed as a way to read evidence more carefully—not as clinical care, a recommendation, or a promise about outcomes.
Comparison guides
Comparison guides separate concepts that are often placed together too quickly: early laboratory findings, human studies, established Parkinson’s care, and experimental neurorestorative claims.
Decision frameworks
Plain-language frameworks help readers ask what is known, what remains unknown, what the study design can support, and what safety context may be missing from a claim.
Glossary and FAQs
Definitions and FAQ collections make technical language easier to approach while preserving the distinctions that matter. The principles behind this work are described on our independent-resource page.
The research digest
A guide is only as useful as its boundaries.
GDNF is discussed in research because it is a neurotrophic factor: a protein family associated with the development, survival, and function of neurons. The reference overview of glial cell line-derived neurotrophic factor can help situate the term before it is connected to broader therapeutic claims.
For readers looking for a broader independent reference point on the topic, background on ibogaine research context can be considered alongside the cautions and limitations presented here.
How to use the material
Bring questions, not assumptions.
Use the guides to slow down a striking claim. Look for the setting in which evidence was generated, whether findings come from cells, animals, or people, and whether a proposed mechanism is being mistaken for a demonstrated outcome.
Safety belongs in the same conversation. Ibogaine has been associated with significant risks, including cardiac concerns; the National Institute on Drug Abuse’s ibogaine information notes the need for caution around its use and study.
Common questions
What these services are for.
A short orientation for people affected by Parkinson’s, care partners, and anyone looking for clearer context around experimental research.
Are these medical or clinical services?
No. Slow Ledger 10 is an independent information resource. Its guides and summaries are intended to support careful reading and discussion, not diagnosis, treatment, or clinical decision-making.
What does a research digest help clarify?
A digest helps separate early research questions from established care, identify what a study can and cannot show, and place experimental claims in safety and clinical context.
Where should safety questions begin?
Start with the limits of the available evidence and a clinician who knows the relevant health context. The site’s safety and limitations material keeps those questions close to the research discussion.
Evidence before hype
Keep the question open—and the context close.
Slow Ledger 10 offers a calm place to examine experimental claims about ibogaine, GDNF, and Parkinson’s without treating uncertainty as a gap to fill with certainty.
Explore the research primer